Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6

31 Mar 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Signaling Pathways in Disease

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40164264
DOI: 10.1016/j.ijbiomac.2025.142667

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6PMID 40164264Read ↗

Evolution of nanobodies specific for BCL11ASemantic proximity Read ↗

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapySemantic proximity Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

Welding PROxAb Shuttles: A modular approach for generating bispecific antibodies via site-specific protein-protein conjugationSemantic proximity Read ↗

bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)Semantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

AI-assisted protein design to rapidly convert antibody sequences to intrabodies targeting diverse peptides and histone modificationsSemantic proximity Read ↗

Precision medicine by designer interference peptides: applications in oncology and molecular therapeuticsSemantic proximity Read ↗

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein DegradationSemantic proximity Read ↗

DARPins: A new generation of protein therapeuticsSemantic proximity Read ↗

Clinical considerations for the design of PROTACs in cancerSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.